Viropro, Inc. (VPRO)

[pgh_maulers]

Post on Yahoo from a long time holder...

I have worked in the pharma/biotech industry since 1997 in Market Research, Marketing, Forecasting and Business development. I now have 700k shares and will not sell any of them below $1.

The following blockbuster biologics are set for patent expiry in the next few years (most recent 12 months sales per Wolters Kluwer):

AVASTIN $ 2,948,199,412.17
AVONEX $ 964,539,225.82
ENBREL $ 2,628,021,606.72
EPOGEN $ 2,988,201,049.86
HERCEPTIN $ 1,487,295,939.74
NEUPOGEN $ 1,006,658,000.38
PEGASYS $ 557,141,142.84
REBIF $ 708,820,724.75
REMICADE $3,387,392,303.18
RITUXAN $ 2,742,198,613.16

Vpro's technology will be utilized to create biosimilars for all of these drugs and thus vpro will receive significant milestone payments and royalties on all sales of these biosimilars.

You might wonder why Vpro was trading under 1 cent prior to this week. The answer is simple. They were operating on a miniscule budget which didn't even allow them a PR or IR firm meaning zero exposure or even auditors thus the pk designation.

With the deal with Spectrum, everything has changed. They will now be able to do all of that. I spoke with Claude Grigras this morning and he said with will soon be hiring auditors and moving back to the regular OTCBB exchange. Also, they have already hired Gilford Securities to act as Strategic advisors.

Clearly, not only is the potential here huge, it is now actually starting to be realized!

Good luck to all,